caa a22 4500 445332263 CHVBK 20180317142741.0 cr unu---uuuuu 170323e20110601xx s 000 0 eng 10.1007/s10198-010-0274-y doi (NATIONALLICENCE)springer-10.1007/s10198-010-0274-y Reimbursement of pharmaceuticals: reference pricing versus health technology assessment [Elektronische Daten] [Michael Drummond, Bengt Jönsson, Frans Rutten, Tom Stargardt] Reference pricing and health technology assessment are policies commonly applied in order to obtain more value for money from pharmaceuticals. This study focussed on decisions about the initial price and reimbursement status of innovative drugs and discussed the consequences for market access and cost. Four countries were studied: Germany, The Netherlands, Sweden and the United Kingdom. These countries have operated one, or both, of the two policies at certain points in time, sometimes in parallel. Drugs in four groups were considered: cholesterol-lowering agents, insulin analogues, biologic drugs for rheumatoid arthritis and "atypical” drugs for schizophrenia. Compared with HTA, reference pricing is a relatively blunt instrument for obtaining value for money from pharmaceuticals. Thus, its role in making reimbursement decisions should be limited to drugs which are therapeutically equivalent. HTA is a superior strategy for obtaining value for money because it addresses not only price but also the appropriate indications for the use of the drug and the relation between additional value and additional costs. However, given the relatively higher costs of conducting HTAs, the most efficient approach might be a combination of both policies. The Author(s), 2010 Pharmaceuticals nationallicence Reimbursement nationallicence Cost-effectiveness analysis nationallicence Health policy nationallicence Drummond Michael Centre for Health Economics, Alcuin ‘A' Block, University of York, YO10 5DD, Heslington, York, UK aut Jönsson Bengt Stockholm School of Economics, Stockholm, Sweden aut Rutten Frans Erasmus University Rotterdam, Rotterdam, The Netherlands aut Stargardt Tom Institute of Health Economics and Health Care Management, Helmholz Zentrum, Munich, Germany aut The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 263-271 1618-7598 12:3<263 2011 12 10198 https://doi.org/10.1007/s10198-010-0274-y text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10198-010-0274-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Drummond Michael Centre for Health Economics, Alcuin ‘A' Block, University of York, YO10 5DD, Heslington, York, UK aut NATIONALLICENCE 700 1- Jönsson Bengt Stockholm School of Economics, Stockholm, Sweden aut NATIONALLICENCE 700 1- Rutten Frans Erasmus University Rotterdam, Rotterdam, The Netherlands aut NATIONALLICENCE 700 1- Stargardt Tom Institute of Health Economics and Health Care Management, Helmholz Zentrum, Munich, Germany aut NATIONALLICENCE 773 0- The European Journal of Health Economics Springer-Verlag 12/3(2011-06-01), 263-271 1618-7598 12:3<263 2011 12 10198 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer